Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : University of Central Lancashire
Deal Size : Undisclosed
Deal Type : Partnership
Central Lancashire And Brinton Healthcare Explore Nanoparticle Therapies
Details : The collaboration will focus on developing innovative skincare therapies using topical nanocarriers for chronic skin diseases such as psoriasis and atopic dermatitis as part of its future projects.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
October 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : University of Central Lancashire
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Brinton Pharmato Launch Favipiravir, a Promising Drug for COVID-19
Details : Favipiravir will be marketed by Brinton Pharmaceuticals under the brand name Faviton. Faviton will be initially launched in 18 countries where Brinton has its own presence. In India, It will be launched once DCGI approval process is completed.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 18, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
